The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; Netcancer; Pfizer
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; Gilead Sciences; GlaxoSmithKline; MSD; Novartis; Pfizer; Sanofi
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; MSD; Netcancer; Pfizer
Research Funding - MSD; Novartis; Pfizer; Seagen
Travel, Accommodations, Expenses - Gilead Sciences; MSD; Pfizer
BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.
 
Helene Blons
Honoraria - AstraZeneca; AstraZeneca; BMS; MSD Oncology
Consulting or Advisory Role - Amgen; AstraZeneca; Lilly; Takeda
 
Justine Abdelli
No Relationships to Disclose
 
Valerie Taly
Employment - Methys
Stock and Other Ownership Interests - Emulseo; Methys
Consulting or Advisory Role - Emulseo
Research Funding - Institut Merieux (Inst); SERVIER (Inst)
Patents, Royalties, Other Intellectual Property - 4 patents related to cancer biomarkers (methylation markers). 2 patents related to covid 19 2 patents related to biomarker detection none of these patents relates to this work.
 
Claire Mulot
No Relationships to Disclose
 
Pierre Laurent Puig
Stock and Other Ownership Interests - Methys
Honoraria - Amgen; AstraZeneca; BIOCARTIS; Merck; MSD Oncology; Roche; Sanofi
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Merck
Patents, Royalties, Other Intellectual Property - Inventor of mir31-3p licence to integragen
Travel, Accommodations, Expenses - Merck; Roche
 
Benoit You
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clovis Oncology; Daiichi Sankyo Europe GmbH; ECS PROGASTRIN; GlaxoSmithKline; Immunomedics; LEK; MSD Oncology; Myriad Genetics; Novartis; Roche/Genentech; Seagen; TESARO
Research Funding - Clovis Oncology (Inst); Merck Serono (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS; MSD Oncology; Roche/Genentech; SEAGEN
 
Philipp Harter
Honoraria - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Lilly; MSD Oncology; Roche; Sotio; Stryker; Zai Lab
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Immunogen; Merck; Roche; Tesaro
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Roche (Inst)
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Corcept Therapeutics; Genmab; GlaxoSmithKline; Immunogen; MSD; Novartis; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; Genmab; GlaxoSmithKline; ImmunoGen; MSD; PharmaMar; Seagen
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Gynecological Cancer InterGroup
 
Yolanda Garcia
Consulting or Advisory Role - GlaxoSmithKline/Tesaro
 
Christian Schauer
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD; Roche
Travel, Accommodations, Expenses - GlaxoSmithKline; MSD
 
Sakari Hietanen
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD
Speakers' Bureau - AstraZeneca; GlaxoSmithKline
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech
Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech
 
Ignace Vergote
Consulting or Advisory Role - Agenus; Akeso Biopharma; AstraZeneca; Bristol Myers Squibb; Deciphera; Eisai; Elevar Therapeutics; Exelixis; Genmab; GlaxoSmithKline; Immunogen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Mersana; MSD; Novartis; Novocure; Oncoinvent; OncXerna Therapeutics; Regeneron; Roche; Sanofi; Seagen; Sotio; Verastem; Zentalis
Research Funding - Amgen (Inst); Oncoinvent (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Genmab; Karyopharm Therapeutics; Novocure
 
Hiroaki Kobayashi
No Relationships to Disclose
 
Thibault De La Motte Rouge
No Relationships to Disclose
 
Paul Buderath
Honoraria - AstraZeneca/Daiichi Sankyo; Roche
Consulting or Advisory Role - Roche
 
Sabrina Chiara Cecere
No Relationships to Disclose
 
Guillaume Bataillon
Consulting or Advisory Role - GlaxoSmithKline (Inst)
 
Eric Pujade-Lauraine
Employment - Arcagy-Gineco
Honoraria - AstraZeneca; GlaxoSmithKline
Consulting or Advisory Role - AGENUS; AstraZeneca; Incyte; Merck; Roche
Research Funding - AstraZeneca (Inst)
Other Relationship - Arcagy-Gineco
 
Isabelle Laure Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; DECIPHERA; Genmab; GlaxoSmithKline; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Blueprint Medicines; BMS; Bristol-Myers Squibb; Clovis Oncology; Daichi; Deciphera; Eisai; Genmab; GlaxoSmithKline; Macrogenics; Mersana; MSD Oncology; Novartis; Novocure; Ose pharma; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES